Guides, research, and insights from Source GLP
301 articlesFull analysis of TRIUMPH-1 Phase 3 topline data: retatrutide 4mg/9mg/12mg efficacy, cardiometabolic outcomes, safety signals, and regulatory timeline.
Cross-trial comparison of retatrutide (TRIUMPH-1), tirzepatide (SURMOUNT-1), and semaglutide (STEP-1) Phase 3 data. Efficacy, safety, and cardiometabolic outcomes.
Oral semaglutide, orforglipron (Foundayo), and amycretin compared. Efficacy, pricing, mechanism, and what the pill revolution means for GLP-1 access.
Complete review of GLP-1 safety signals: pancreatitis, thyroid cancer, gastroparesis, NAION, hair loss, ED, and gallbladder events. Evidence quality assessed.
Tirzepatide projected at $45B in 2026 sales. Semaglutide at $39.5B. Market analysis of the $84.5B GLP-1 pharmaceutical landscape.
GLP-1 insurance coverage timeline 2026: Medicare Bridge $50/month copay, Medicaid expansion, commercial plan trends, and the prior authorization playbook.
GLP-1 medications reduce alcohol cravings by 41%, decrease smoking urge, and show signals across multiple substance use disorders. Complete evidence review.
Complete decoded breakdown of Zepbound vial pricing by dose, channel, and commercial structure.
On December 20, 2024, the FDA approved Zepbound as the first-ever medication for obstructive sleep apnea. Here's what the SURMOUNT-OSA trial actually showed.
What happens when you stop semaglutide or tirzepatide? We analyze the STEP 1 extension, SURMOUNT-4, and real-world data on weight regain and prevention strategies.
FDA approved semaglutide 7.2mg on May 13, 2026. STEP UP trial: 20.7% weight loss, 1 in 3 achieving 25%+. The sourced data breakdown.
Complete timeline of Wegovy's $349 NovoCare cash-pay price cut and subsequent market changes.
Complete explainer on the TrumpRx federal drug portal and what it means for GLP-1 access.
Tirzepatide vs semaglutide compared on the SURMOUNT-5 NEJM 2025 head-to-head data: 20.2% vs 13.7% weight loss, side effects, dose ladders, current 2026 cash prices, and who should
A comprehensive comparison of Mounjaro/Zepbound (tirzepatide) vs Ozempic/Wegovy (semaglutide). Weight loss data, side effects, mechanisms, and which might work better for you.
Everything you need to know about tirzepatide (Mounjaro/Zepbound). How it works, dosing, what to expect, and why it's different from semaglutide.
Deep evidence review of the SYNERGY-NASH trial of tirzepatide for MASH/NASH liver disease.
Deep evidence review of the SURPASS-CVOT trial of tirzepatide for diabetic cardiovascular disease.
Evidence review of SURMOUNT-OSA, the trial that made tirzepatide the first drug FDA-approved for OSA.
Why do Ozempic and Wegovy cause rotten egg burps? The science of delayed gastric emptying, hydrogen sulfide, and evidence-based relief strategies.
The FDA's comment deadline is June 29, 2026. Should patients order extra compounded semaglutide now? We source the facts on shelf life, legality, and risk.
Evidence review of the complete STEP clinical trial program for semaglutide weight management.
Evidence review of the STEP HFpEF trial of semaglutide for heart failure with preserved ejection fraction.
Active state AG investigations into GLP-1 telehealth companies and what they mean for the industry.
Sprout Health tirzepatide pricing for 2026: what you'll pay per month, what's included, how it compares to other providers, and whether it's worth it.
Sprout Health GLP-1 review with BBB, Trustpilot, and customer complaint data. Compounded semaglutide $249/mo, tirzepatide $299/mo. Honest pros, cons, and who it actually fits.
Independent Sprout Health review. Compounded semaglutide $249/month, tirzepatide $299/month. Partner pharmacies, state availability, price-lock guarantee, customer review patterns,
Sprout Health GLP-1 pricing: compounded semaglutide $249/mo, tirzepatide $299/mo. First-month promos, 3-month plans, state availability, and price-lock explained. Sourced.
How to find legitimate GLP-1 medications online in 2026. Red flags to watch for, verified providers, and how to avoid scams in the booming weight loss market.
A week-by-week guide to Ozempic and Wegovy side effects. When nausea peaks, when it fades, and what symptoms warrant calling your doctor.
Head-to-head comparison of semaglutide and tirzepatide. Efficacy, side effects, cost, and who each medication works best for.
SURMOUNT-5 trial data compared: tirzepatide achieved 20.2% weight loss vs semaglutide's 13.7% at 72 weeks. Full breakdown of cost, side effects, and access.
Bariatric surgery delivers 25–35% sustained weight loss; semaglutide delivers ~15%; tirzepatide ~21%. Surgery wins on magnitude. Medications win on invasiveness and reversibility
The FDA declared the semaglutide shortage resolved on February 21, 2025. The compounding pathway closed in April–May 2025. Here's the current status, the litigation that's still
Full timeline for when generic semaglutide actually arrives at U.S. retail pharmacies.
FDA approves semaglutide for MASH with liver fibrosis. Breaking down the ESSENCE trial data: 63% resolution of steatohepatitis, 37% fibrosis improvement.
Wegovy becomes the first GLP-1 approved for fatty liver disease (MASH). ESSENCE trial showed 63% achieved resolution of liver inflammation vs 34% on placebo.
The first placebo-controlled trial of semaglutide for alcohol use disorder shows reduced drinking, cravings, and heavy drinking days. Full study breakdown.
Everything you need to know about semaglutide. How it works, what to expect, dosing, side effects, and results from clinical trials.
The SELECT trial proved semaglutide reduces cardiovascular events in people without diabetes. Full analysis of the landmark study that changed GLP-1 treatment.
Complete analysis of the SELECT trial that proved semaglutide reduces heart attacks, strokes, and cardiovascular death in people without diabetes. 17,604 patients, 20% risk reducti
Deep evidence review of the SELECT cardiovascular outcomes trial and its extended follow-up.
Complete map of the authorized telehealth partnerships for Wegovy and Zepbound distribution.
Retatrutide is Lilly's triple hormone agonist showing the highest weight loss yet—28.7% in Phase 3 trials. Here's everything we know about the Triple G drug.
Eli Lilly's retatrutide achieves 28.7% weight loss (71 lbs) in TRIUMPH-4 Phase 3 trial. First triple-agonist GLP-1/GIP/glucagon results analyzed.
Evidence review of retatrutide phase 2 data and the TRIUMPH phase 3 program.
Complete analysis of Eli Lilly's retatrutide (LY3437943): 28.7% weight loss in TRIUMPH trials, how triple agonism works, side effects including dysesthesia, and 2027 approval timel
Complete reference on retail pharmacy cash-pay pricing for GLP-1 medications in 2026.
Penn researchers analyzed 410,198 Reddit posts with AI to surface GLP-1 side effects missing from clinical trials. Full source file with primary citations.
Protein requirements on Ozempic and Wegovy: research-based recommendations, how to hit targets when appetite is suppressed, and why it matters for muscle.
Explainer on PBM rebate economics and how they affect GLP-1 copays vs cash-pay pricing.
Ozempic requires a valid prescription in the US. Here's why, what the legal requirements are, and how to access it legitimately.
Weight loss plateaus on GLP-1 medications are normal, typically hitting around week 60. Here's the science behind why it happens and evidence-based strategies to break through.
GLP-1 medications carry a black box warning for thyroid cancer based on rodent studies. Here's what the research shows about actual risk in humans.
A week-by-week guide to GLP-1 side effects. When nausea starts, peaks, and resolves. When to call your doctor. What's normal vs. concerning.
Plateaus on semaglutide are not failures — they are the well-documented endpoint observed in STEP 1, STEP 5, and SELECT. Here's what the trial data show about when weight loss fl
Men on semaglutide report their penis 'got bigger.' We talked to Yale urologists and reviewed the research. Here's what the evidence actually shows.
Up to 15-23% of people don't lose significant weight on GLP-1 medications. Here's what the science says about non-responders and what options exist.
FDA approves semaglutide for chronic kidney disease in type 2 diabetes. FLOW trial showed 24% reduced risk of kidney failure. Full trial analysis.
Will Ozempic cause loose skin? We explain 'Ozempic face,' skin laxity after rapid weight loss, who's at risk, and treatment options.
Ozempic face refers to facial sagging and hollowing from rapid weight loss. Here's what causes it, who's at risk, and evidence-based prevention strategies.
Rapid GLP-1 weight loss can cause facial volume loss, sagging skin, and premature aging. Here's what dermatologists and plastic surgeons say—with data.
Thousands report strange, vivid dreams on semaglutide. Shopping with Clint Eastwood, robbing museums with celebrities. Here's the neuroscience and what Novo Nordisk says.
Why women on GLP-1 medications are reporting unexpected pregnancies. The science behind fertility restoration, birth control absorption, and what you need to know.
Why are women getting pregnant on Ozempic? We explain the science behind restored fertility, birth control concerns, and what the research shows.
The Ozempic baby boom is real. Here's the science behind why GLP-1 medications can boost fertility, potentially interfere with birth control, and what's known about pregnancy safet
Randomized trial data confirms semaglutide reduces alcohol consumption. The neuroscience of why GLP-1 drugs decrease drinking—verified with sources.
Eli Lilly's orforglipron: 14.7% weight loss in a daily pill, no fasting required, projected $200-350/month pricing. ATTAIN trial results and 2026 approval timeline.
Orforglipron is Lilly's once-daily oral GLP-1 pill showing 12.4% weight loss in trials. FDA submission filed. What you need to know about this game-changer.
Eli Lilly's orforglipron has an FDA decision date of April 10, 2026. In head-to-head trials, it outperformed oral semaglutide on weight loss and blood sugar control.
Eli Lilly's orforglipron is a non-peptide oral GLP-1 with no food restrictions. Expected FDA decision by end of 2026. Here's what the Phase 3 data shows.
Evidence review of orforglipron's ACHIEVE and ATTAIN phase 3 trials for the first truly convenient oral GLP-1.
Oral Wegovy was approved December 2025 — the first GLP-1 pill for weight loss. Here's what the clinical data shows, what it costs, and how to get it.
Oral Wegovy launched January 2026 at $149/month. Five months in, here's what the early real-world data and patient experience reveal.
Oral semaglutide (Rybelsus) has 0.4-1% bioavailability vs. 89% for injectable. Here's the complete pharmacokinetic comparison and what it means for efficacy.
Rybelsus maxes out at 14mg for diabetes. Oral Wegovy delivers 25mg for weight loss. Same molecule, radically different results. Here's the clinical comparison.
An NIH-funded Nature study found oral GLP-1 drugs like Foundayo reach the central amygdala to suppress pleasure-based eating through a separate mechanism from injectables.
Novo Nordisk's latest earnings paint a clear picture of GLP-1 supply, demand, and pricing strategy. Here's what the financial data means for patients.
Novo Nordisk has filed 111+ lawsuits against compounding pharmacies and telehealth companies. Track every case, outcome, and what it means for compounded semaglutide.
What Novo Nordisk and Eli Lilly's SEC filings say about 2026 GLP-1 pricing and competition.
2026 GLP-1 revenue forecasts for Novo Nordisk and Eli Lilly, with Wegovy and Zepbound breakdowns.
Inside the March 9, 2026 Novo Nordisk-Hims & Hers settlement that ended the compounded semaglutide war.
Retatrutide delivers 28.7% weight loss in Phase 3. Amycretin hits 22%. Orforglipron offers needle-free daily pill. Complete trial data on what's coming next.
The Medicare GLP-1 Bridge launches July 2026 offering Foundayo, Wegovy, and Zepbound KwikPen for $50/month. Complete eligibility guide with plan types and formulation details.
Full breakdown of the Medicare 71% Ozempic discount and what it means for 2027 GLP-1 access.
International GLP-1 price arbitrage analysis — what channels remain economically meaningful in 2026.
GLP-1 delivery methods compared. Needles vs pills vs drops. Pros, cons, and which format fits your lifestyle.
How the HRSA 340B program creates a hidden GLP-1 pricing channel through hospitals and FQHCs.
Step-by-step guide to starting GLP-1 treatment in 2026. Eligibility, telehealth vs PCP, injectable vs oral, insurance vs cash-pay, and what to expect in your first week.
The exact process from quiz to delivery. How telehealth GLP-1 prescriptions work, what to expect, and how long it takes.
A Johns Hopkins analysis published in JAMA Internal Medicine found women lost an average of 11% body weight versus 7% for men. But the drugs work equally w
GLP-1 medications aren't for everyone. Contraindications, cautions, and conditions that may make these drugs inappropriate.
Complete guide on when to pause or stop semaglutide and tirzepatide. Covers pre-surgery protocols, pregnancy planning, adverse events, weight plateaus, and what happens when you st
An honest look at the unanswered questions about GLP-1 medications. What the long-term data is missing and what we're still learning.
Practical nutrition guidance for Ozempic, Wegovy, and Mounjaro. What to eat, what to avoid, and how to maximize results while minimizing side effects.
Weight loss stopped on Ozempic? Research shows plateaus typically occur around 60-68 weeks. Here's why it happens and what to do about it.
A practical 7-day meal plan for your first week on Ozempic, Wegovy, or Mounjaro. Nausea-friendly foods, protein priorities, and easy recipes.
Comparing GLP-1 medications to bariatric surgery. Outcomes, reversibility, costs, and how to decide which approach is right for you.
What the research shows about semaglutide and NAION (nonarteritic anterior ischemic optic neuropathy). The JAMA study, FDA FAERS data, risk factors, and what you should watch for.
What we know (and don't know) about Ozempic, Wegovy, and tirzepatide in adults over 75. Trial exclusions, frailty concerns, and when GLP-1s may still make sense.
Retatrutide targets three receptors: GLP-1, GIP, and glucagon. How triple agonism could deliver even greater weight loss than current medications.
How to travel with Ozempic, Wegovy, or Mounjaro. TSA rules, temperature storage, and international considerations.
Separating fact from fiction on the most viral GLP-1 claims. What the science actually says about common Ozempic myths.
The facts on semaglutide, tirzepatide and thyroid cancer risk. Understanding the FDA Black Box Warning, rodent studies vs human data, and who should not take GLP-1 medications.
Research shows GLP-1 medications can increase testosterone levels in men with obesity by 18% on average. Here's the complete data on hormonal effects.
Why does food taste different on semaglutide? New research shows GLP-1 drugs actually change taste bud gene expression and brain response to sweetness.
Complete guide to switching from semaglutide to tirzepatide or between GLP-1 providers: when to switch, dose conversion, avoiding gaps, and what to expect.
The dreaded sulfur burps on GLP-1 medications. Why they happen, foods that trigger them, and proven strategies to reduce or eliminate this embarrassing side effect.
No fake testimonials — real clinical trial outcomes. From STEP to SURMOUNT to retatrutide, here's what the evidence says is possible with GLP-1 medications.
What happens when you stop Ozempic or Zepbound? The STEP-1 extension data on weight regain, tapering strategies, and when you actually need to stop permanently.
Can Ozempic help you quit smoking? We analyze the Annals of Internal Medicine study, active clinical trials, and the science behind GLP-1s and nicotine addiction.
Two randomized trials. One positive pilot, one negative larger study. A 220,000-patient observational signal. Two new RCTs enrolling. Here's exactly what the smoking-cessation evid
Tirzepatide dramatically reduced sleep apnea severity in obese patients, potentially offering an alternative to CPAP. NEJM results show up to 63% AHI reduction.
Tirzepatide becomes the first medication ever approved to treat obstructive sleep apnea. What the SURMOUNT-OSA trial showed and what it means for 30 million Americans.
Practical, evidence-based strategies for managing nausea, constipation, and other common GLP-1 side effects. What works and what doesn't.
GLP-1 users report reduced compulsive shopping. No studies exist, but the dopamine science is intriguing. We separate anecdotes from theory.
People report their urge to shop has vanished on GLP-1 medications. Why dopamine-driven retail therapy may be the latest 'addiction' these drugs affect.
When to inject Ozempic or Mounjaro with irregular work hours. Practical guidance for nurses, factory workers, and anyone with rotating or night shifts.
Compounded semaglutide lasts 28-90 days. Brand-name Ozempic: 24 months. Oral Wegovy: no refrigeration needed. A sourced storage and shelf life reference.
Are GLP-1 medications legit? We reviewed the clinical trial data, real patient outcomes, and what to realistically expect from semaglutide and tirzepatide for weight loss.
Stanford researchers found ~10% of people carry PAM gene variants that make GLP-1 drugs less effective. Here's what the science says and what it means for your treatment.
GLP-1 receptors aren't just in your gut—they're in your brain, heart, kidneys, and more. Understanding receptor locations explains why these drugs have such wide-ranging effects.
People are reporting they quit smoking on Ozempic without trying. The science behind GLP-1s and nicotine addiction, plus active clinical trials.
Emerging evidence that GLP-1 weight loss may improve psoriasis severity. The obesity-inflammation-psoriasis connection and what patients are reporting.
Researchers are calling GLP-1 medications a potential paradigm shift for addiction treatment. What the 12+ clinical trials mean for the future of treating compulsive behaviors.
Protein requirements while on Ozempic, Wegovy, or Mounjaro. How much to eat, best sources, and strategies for when appetite is low.
The raw ingredient for a month of Ozempic costs under $50. So why does a prescription cost $1,000+? Breaking down the GLP-1 pricing chain with sources.
Can you use Ozempic or Wegovy after gastric sleeve or bypass? Evidence on weight regain treatment, safety considerations, and which post-bariatric patients are candidates.
Complete guide to next-gen GLP-1 drugs: CagriSema, Amycretin, Survodutide, VK2735, and more. Efficacy rankings, mechanisms, timelines, and how they compare to current medications.
Retatrutide, CagriSema, orforglipron, amycretin, and monthly injectables — the next generation of GLP-1 medications is coming. Here's every pipeline drug worth watching.
How semaglutide and tirzepatide stay active for a week when natural GLP-1 lasts only minutes. The science of half-life, albumin binding, and steady-state levels.
How Ozempic and Wegovy work during perimenopause. Addressing hormonal weight gain, interactions with HRT, and what the research shows for women 40-55.
FDA-approved GLP-1 medications for adolescents 12+. STEP TEENS trial data, safety considerations, and what the AAP recommends for childhood obesity treatment.
Complete analysis of GLP-1 clinical trials in adolescents. STEP TEENS results, liraglutide pediatric data, and ongoing tirzepatide studies in children and teens.
How semaglutide and tirzepatide are helping women with PCOS. The connection between insulin resistance, weight loss, and hormonal balance.
Lixisenatide stopped motor symptom progression in early Parkinson's patients. Here's what the NEJM trial found and what's coming next.
The facts on semaglutide, tirzepatide and pancreatitis risk. Symptoms to watch for, who's at higher risk, and why you must stop permanently if it occurs.
Two recent meta-analyses, two different headlines. A 51,346-patient-year semaglutide/tirzepatide dataset showing OR 0.99. A class-wide RR 1.44 that disappears when stratified by ba
Duke University scientists discovered that your pancreatic alpha cells — long thought to only produce glucagon — actually generate powerful amounts of GLP-
Head-to-head comparison of the major GLP-1 medications. Differences in weight loss, mechanism, dosing, side effects, and cost.
Can semaglutide reduce opioid cravings? Penn State researchers found a 40% reduction in cravings in early trials. Here's the data from NIH-funded studies.
10-15% of people don't respond well to GLP-1 medications. The science behind non-response and what to try next.
What's coming after Ozempic and Mounjaro? Retatrutide, orforglipron, and the next wave of obesity medications in clinical trials.
Comprehensive analysis of body composition data from STEP, SURMOUNT, and SURPASS trials. What DXA and MRI studies reveal about semaglutide and tirzepatide effects on lean mass.
A realistic timeline of your GLP-1 journey. What happens month 1, month 3, month 6, and beyond. Setting proper expectations.
Complete guide to GLP-1 medications during and after menopause. HRT compatibility, targeting visceral fat, bone health monitoring, and cardiovascular benefits for postmenopausal wo
Semaglutide received FDA approval for MASH in August 2025—the second drug ever approved for fatty liver disease. Phase 3 trial data, tirzepatide pipeline, and what it means.
A data-driven look at the GLP-1 telehealth market 14 months after the FDA's enforcement wave. Which providers survived, which didn't, and what the landscape looks like now.
Complete guide to managing nausea on semaglutide and tirzepatide: why it happens, how long it lasts, foods that help, medications like Zofran, and when to call your doctor.
From 6 FDA approvals to Alzheimer's prevention to addiction reduction: a complete, sourced scorecard of everything GLP-1 medications can — and can't — do in 2
The FLOW trial was stopped early because semaglutide worked so well for kidney disease. What the data shows and what it means for millions with CKD.
The landmark FLOW trial showed semaglutide reduced major kidney events and death in diabetic kidney disease. Published in NEJM, stopped early for efficacy.
Is combining a ketogenic diet with Ozempic or Mounjaro safe and effective? Potential benefits, risks, and practical considerations for keto on GLP-1 medications.
Navigate GLP-1 insurance in 2025: Medicare/Medicaid coverage by state, commercial plan restrictions, prior auth strategies, appeal tactics, and manufacturer savings programs up to
Strategies for getting GLP-1 medications covered by insurance, manufacturer savings programs, and alternative options when coverage fails.
Complete guide to injecting semaglutide and tirzepatide: best injection sites, rotation patterns, preparation steps, and techniques for reducing pain and anxiety.
New data suggests GLP-1 drugs may reduce inflammation markers and autoimmune disease risk. Here's what the research shows for rheumatoid arthritis, psoriasis, and IBD.
The SELECT trial proved semaglutide reduces cardiovascular risk by 20% in people with obesity — even without diabetes. Here's what this landmark study means for patients.
Semaglutide dramatically improved symptoms and quality of life in heart failure patients. What the STEP-HFpEF trial means for millions living with HFpEF.
Harvard and Brigham researchers found that GLP-1 medications improved heart failure with preserved ejection fraction by 40% — a condition that has historic
Is GLP-1 hair loss real? We reviewed every FAERS analysis, cohort study, and dermatology paper. Here's what the data actually shows.
GLP-1 is a key messenger between your gut and brain. Understanding this communication system explains appetite, satiety, food noise, and why these medications work.
GLP-1 medications may help gout by lowering uric acid levels. The obesity-gout connection, research on semaglutide and uric acid, and what patients report.
Users report GLP-1s curb gambling and shopping urges. We analyze the anecdotal reports, dopamine science, and why no clinical trials exist yet.
Reports of gambling urges disappearing on GLP-1 medications. The dopamine connection, viral stories, and what researchers think is happening.
Why rapid weight loss from semaglutide and tirzepatide increases gallstone risk. Symptoms to watch for, when to pause treatment, and whether you can restart after gallbladder surge
The constant mental chatter about food that vanishes on GLP-1 medications. What causes food noise, why some brains are louder, and how semaglutide silences it.
Food noise is the constant mental chatter about eating. Here's what it means, why some people have it, and how GLP-1 medications turn down the volume.
At a 2025 Copenhagen conference, researchers from Novo Nordisk and Eli Lilly proposed something extraordinary: GLP-1 medications may be the first true anti
Exenatide and liraglutide trials for alcohol and cocaine showed mixed results. Why researchers think semaglutide's different pharmacology could change outcomes.
What does science actually say about 'Ozempic babies'? Complete analysis of GLP-1 fertility research in PCOS, weight loss effects, birth control interactions, and pregnancy safety
Complete chronological history of GLP-1 medication FDA approvals. From Byetta (2005) to today's expanded indications for cardiovascular protection, sleep apnea, and kidney disease.
Semaglutide shows remarkable results for MASH (fatty liver disease). What the ESSENCE trial found and why FDA granted Breakthrough Therapy designation.
How to exercise while on Ozempic, Wegovy, or Mounjaro. Why resistance training is essential and how to optimize your workouts.
GLP-1 eligibility breakdown: BMI requirements for Wegovy and Zepbound, FDA-approved criteria, what insurance actually demands, and why telehealth platforms approve at lower thresho
Evidence-based guide to Ozempic, Wegovy, and other GLP-1s for seniors. Clinical trial data on adults 65+, muscle loss prevention, and special considerations from the SELECT and FLO
Complete guide to GLP-1 medication interactions with insulin, sulfonylureas, birth control, levothyroxine, warfarin, and alcohol. Based on FDA labels and 2025 ADA guidelines.
STEP 1 extension data shows most patients regain weight after stopping semaglutide. Here's what the research says about discontinuation.
FDA and EMA investigations, FAERS data, WHO database analysis, and controlled studies on semaglutide and mental health. The complete picture with sources.
A major study published in The Lancet Psychiatry found that GLP-1 medication users had significantly fewer psychiatric hospital visits, less work absence d
A massive matched cohort study found GLP-1 medication users had a 70% reduced risk of developing dementia compared to non-users. The numbers are striking —
The EVOKE trial of semaglutide for Alzheimer's didn't show benefit. But observational data suggests protection. Here's what we know about GLP-1s and brain health.
Fake Ozempic and Wegovy are circulating. How to identify counterfeit GLP-1 medications and protect yourself from dangerous fakes.
An honest analysis of GLP-1 medication costs vs benefits. What the health economics research says about value.
How to evaluate compounding pharmacies for semaglutide and tirzepatide. 503A vs 503B explained, PCAB accreditation, COA verification, FDA warning signs, and 15 questions to ask bef
The FDA declared semaglutide and tirzepatide shortages resolved. Here's what's still legal for compounding, the clinical difference exception, pending lawsuits, and what it means f
The truth about compounded GLP-1 medications. What we know about safety, quality concerns, and how to minimize risk.
A UC San Diego study of 6,800+ colon cancer patients found that those taking GLP-1 medications had a 5-year mortality rate of 15.5% compared to 37.1% for n
Emerging research on semaglutide for cocaine and stimulant use disorders. What the science shows and what trials are underway.
Semaglutide reduced cocaine self-administration by 26% in rats and cocaine-seeking by 62%. We analyze the University of Gothenburg study and $2.7M UTHealth trial.
Comprehensive database of major GLP-1 and incretin clinical trials. SURMOUNT-5 head-to-head, ACHIEVE-1 orforglipron, ATTAIN obesity results, REDEFINE CagriSema, TRIUMPH retatrutide
GLP-1s show promise for fatty liver, but what about cirrhosis? Evidence, safety concerns, and why advanced liver disease requires special consideration.
How GLP-1 weight loss medications may improve chronic pain conditions. The obesity-pain connection, anti-inflammatory effects, and what patients report.
When Oprah and other celebrities started talking openly about weight loss medications, the conversation changed. The cultural shift from secret shame to mainstream acceptance.
A study of 680,000+ patients found semaglutide users were 44-60% less likely to develop cannabis use disorder. We break down the Wang et al. 2024 findings.
A 2024 study found 44% lower cannabis use among patients on GLP-1 medications. What the research shows about marijuana, dopamine, and these drugs.
Can cancer survivors safely use Ozempic or Wegovy? Evidence on GLP-1s after cancer treatment, weight management, and special considerations for cancer history.
Duke Cancer Institute found that obesity shuts down the immune system's ability to fight cancer. In animal models, GLP-1 medications restored immune functi
GLP-1 receptors in the VTA, nucleus accumbens, and prefrontal cortex may explain why these drugs affect cravings. A visual guide to the neuroscience.
Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Rybelsus, and Saxenda all carry the same FDA boxed warning for thyroid C-cell tumors. What MTC and MEN 2 mean, who's contraindicated
Can you use Ozempic or tirzepatide while preserving muscle? Body composition data, cutting phase strategies, and what bodybuilders need to know about GLP-1s.
GLP-1 medications access your brain directly. Understanding how they cross the blood-brain barrier explains appetite control, food noise reduction, and potential effects on addicti
Can Ozempic help binge eating disorder? The research on GLP-1 medications for BED and compulsive eating patterns.
GLP-1 medications do far more than help you lose weight. From heart protection to addiction reduction, here are 7 evidence-backed benefits you should know about.
The American Society of Anesthesiologists' 2023 GLP-1 preoperative guidance was significantly updated in October 2024. What changed, who needs to hold their dose, who can continue,
Weight loss reduces AFib burden significantly. How GLP-1 medications may help atrial fibrillation through weight loss and beyond.
GLP-1 medications aren't banned by WADA, but athletes face unique considerations. Weight-class sports, muscle preservation, endurance effects, and the ethics debate.
How Ozempic and Wegovy affect athletic performance, muscle mass, endurance, and recovery. WADA status, professional athlete considerations, and sports-specific guidance.
If GLP-1s dampen the reward system, could they reduce pleasure from everything—not just food and drugs? What we know about anhedonia risk.
Some people report reduced enjoyment of food, hobbies, and life on GLP-1 medications. What does the science say about this concern?
The EVOKE trials testing semaglutide for Alzheimer's disease failed their primary endpoints in November 2025. Here's what the data actually showed and what it means.
The first randomized controlled trial of semaglutide for alcohol use disorder is here. We break down exactly what the February 2025 JAMA Psychiatry study found.
A major JAMA Psychiatry study found 50-56% lower alcohol use disorder among GLP-1 patients. The science behind why Ozempic makes people drink less.
Can you drink alcohol on Ozempic or Zepbound? The science on GLP-1 alcohol interactions: hypoglycemia risk, slower metabolism, reduced cravings, and liver protection research.
Complete GLP-1 pricing guide for 2026. Oral pills from $149/mo, injectable options from $150-350, cash-pay discounts, and every way to save on treatment.
A study of over 600,000 veterans found GLP-1 users were 15-20% less likely to misuse alcohol, opioids, cannabis, cocaine, or nicotine. No other drug has ev
Your complete prep list before starting GLP-1 treatment. Documents, supplies, questions to ask, and how to set yourself up for success.
A study of 86,000+ adults found that GLP-1 medication users had 17% fewer new cancer diagnoses. The strongest signals were for endometrial cancer, ovarian
How to spot sketchy GLP-1 telehealth providers. Red flags, warning signs, and what legitimate providers do differently.
Practical solutions for GLP-1 nausea. What causes it, when it improves, and 8 strategies that actually work.
The quick primer on GLP-1 medications. What they are, how they work, and whether they're right for you. No medical jargon, just facts.
GLP-1 eligibility explained. BMI requirements, medical conditions, and common myths busted. Find out if you qualify.
Real GLP-1 prices from real providers. What you'll actually pay for semaglutide and tirzepatide in 2025, including brand-name and compounded options.
Practical fixes for GLP-1-related constipation. Why it happens and what to do about it.
What is 'food noise' and why do GLP-1 medications quiet it? The neuroscience of appetite signaling, reward pathways, and the experience patients describe as food freedom.
fMRI brain imaging reveals how GLP-1 medications reduce food cravings and intrusive food thoughts. Primary research from Nature Medicine and clinical trials.
Evidence review of the FLOW trial of semaglutide for diabetic chronic kidney disease.
Complete analysis of the FLOW trial: semaglutide reduced major kidney events by 24%, CV events by 18%, and death by 20% in T2D patients with CKD. Full data and methodology.
Day-by-day guide to your first week on GLP-1 medication. What's normal, what's not, and how to set yourself up for success.
The FDA sent 50+ warning letters to GLP-1 compounders in September 2025. We've compiled every letter with analysis of what triggered enforcement.
Full breakdown of the FDA's March 3, 2026 warning letters to 30 compounded GLP-1 telehealth companies.
The FDA issued 80+ warning letters to GLP-1 compounders in 2025-2026. What the letters say, who was targeted, and what it means for your treatment.
The FDA resolved the semaglutide shortage in February 2025. Here's the full timeline, what happened to compounding, and what your options are in 2026.
Full timeline of how the FDA ended the semaglutide and tirzepatide shortages and reshaped the GLP-1 market.
Complete FDA approval timeline for every GLP-1 medication: Byetta, Victoza, Tanzeum, Trulicity, Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Foundayo. Plus Zepbound OSA (Dec 2024
FDA GLP-1 compounding enforcement actions in 2026. Warning letters, 503A vs 503B legal status, shortage declarations, and which pharmacies are still operating legally.
We analyzed FDA FAERS data on compounded semaglutide and tirzepatide adverse events. Here's how 2026 compares to 2025 — and what the numbers actually tell us.
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from 503B compounding. Every claim sourced from the Federal Register and FDA statements.
The FDA cites 455+ adverse events from compounded semaglutide. What do the reports actually show? We source the data and provide context.
Fact check of the SURMOUNT-5 head-to-head trial comparing tirzepatide to semaglutide.
Fact check on 'Ozempic face' — what dermatologists actually say about facial volume changes on GLP-1s.
Fact check comparing oral Wegovy to injectable Wegovy for weight management.
Fact check on the GLP-1 thyroid cancer black box warning and actual human risk data.
Fact check on GLP-1 muscle loss claims versus the actual body composition trial data.
Fact check on GLP-1 birth defect claims circulating on social media.
Fact check on GLP-1 medications for alcohol use disorder — what evidence supports the claim.
Fact check on the current legal status of compounded tirzepatide post-shortage.
Fact check on whether compounded semaglutide is really as effective as brand-name Wegovy.
Fact check of the viral '1 in 5 Americans on GLP-1s' statistic against actual survey data.
Novo Nordisk's EVOKE and EVOKE+ trials — 3,808 participants across 40 countries, the largest GLP-1 neurodegeneration program ever conducted — returned negative on the primary c
Complete analysis of the EVOKE and EVOKE+ Phase 3 trials. Semaglutide didn't slow Alzheimer's progression, but biomarker data and observational studies suggest prevention potential
Analysis of employer health plan coverage for GLP-1 medications in 2026.
Complete investigation into which compounding pharmacies are still legally operating post-crackdown.
FDA testing found compounded semaglutide potency ranging 42-170% of labeled dose. FAERS reports 442 adverse events. Here's the complete safety comparison.
Current compounded GLP-1 pricing vs. brand-name cash-pay programs in 2026.
We compiled compounded and brand-name GLP-1 pricing from verified provider websites. Every option ranked from cheapest to most expensive.
Independent lab testing of compounded semaglutide found products ranging from 42% to 170% of labeled potency. Here's what the data reveals about quality variation.
FDA testing data, Novo Nordisk analyses, and independent assays reveal wide potency variation in compounded semaglutide—from 0% to over 120% of labeled strength.
Which celebrities have actually admitted to using Ozempic, Wegovy, or Mounjaro? We tracked down the direct quotes — no speculation, just confirmed statements.
Evidence review of the CagriSema combination therapy trials and its competitive positioning vs tirzepatide.
CagriSema combines semaglutide with cagrilintide (amylin analog). Phase 3 results expected 2026, targeting ~25% weight loss. Full mechanism and trial analysis.
Byetta (exenatide) was discontinued by AstraZeneca in October 2024. A generic version exists from Amneal. Here's the current availability status and better GLP-1 alternatives in 20
Every way to save on GLP-1 weight loss medications in 2026. Brand-name pills from $149/mo, compounded injectables from $146/mo, and new savings programs.
Complete implementation timeline for the CMS BALANCE Model and expanded Medicare GLP-1 coverage.
Viking Therapeutics' VK2735 (amycretin-type dual agonist) showed up to 14.7% weight loss in just 13 weeks. Here's what the Phase 2 data means for the GLP-1 pipeline.
A massive VA study found GLP-1 drugs reduce substance use disorders across opioids, cocaine, nicotine, alcohol, and cannabis by 15-25%. Here's what the data actually shows
State-regulated compounding pharmacy or FDA-regulated outsourcing facility? The structural difference shaped the entire compounded GLP-1 market — and now shapes what's legal post
Understand the FDA's 503A and 503B compounding designations. Learn how they affect your semaglutide and tirzepatide prescriptions, quality standards, and what certifications to loo
The FDA's 503B proposal doesn't directly target 503A pharmacies. Here's why 503A compounding operates under different rules and what it means for patient
The BELIEVE trial (NCT05616013), published in Nature Medicine March 2026, is the first randomized trial to demonstrate pharmacological muscle preservation during GLP-1 therapy. 507
Sprout Health offers compounded semaglutide at $249/month and tirzepatide at $299/month with locked pricing at any dose. Full 2026 review covering cost, process, and legitimacy.
GobyMeds offers compounded semaglutide from $99/month and tirzepatide from $133/month with no membership, free consultation, and free overnight shipping. Full 2026 review.
How does GLP-1 medication compare to gastric bypass and sleeve gastrectomy? We compared weight loss outcomes, costs, risks, recovery time, and long-term data.
Not losing weight on GLP-1 medication? 10-15% of patients are slow or non-responders. Here's why it happens, what the research says, and evidence-based strategies to improve your r
CagriSema produced 22.7% weight loss in REDEFINE 1. SURMOUNT-5 showed tirzepatide beats semaglutide head-to-head. What these trials mean for the future of obesity treatment.
In 2023, the EMA launched a safety review of GLP-1 drugs and suicidal ideation. In 2024, they concluded: no causal link found. Here's the complete evidence, including the FDA's par
GLP-1 drugs slow gastric emptying, raising concerns about aspiration during anesthesia. The ASA updated its guidelines in 2023. Here's what surgeons and anesthesiologists need to k
Rapid weight loss from any cause increases gallstone risk. GLP-1 drugs are no exception. Here's the actual incidence data from STEP, SURMOUNT, and SELECT trials, the mechanism, and
CMS announced the BALANCE Model in December 2025 to expand GLP-1 access through Medicare and Medicaid. Copays capped at $50/month. Medicaid launch expected May 2026, Medicare Part
Semaglutide patents expire December 2031, tirzepatide January 2036. Generic liraglutide arrived in 2024. Full patent landscape, settlement details, biosimilar pathway, and internat
STEP TEENS: semaglutide produced a 17% BMI reduction in adolescents aged 12-17 with obesity. 45% dropped below the clinical obesity threshold. NEJM 2022. Complete trial data and pe
Wegovy costs $1,349/month in the US, under $200 in Germany, and as little as $40 in India. Here's the country-by-country pricing breakdown and the structural reasons behind the gap
Insurance coverage for GLP-1 weight loss drugs varies dramatically by state, employer, and plan type. Some states mandate coverage; many Medicaid programs still exclude anti-obesit
Meta-analysis of 40 RCTs: GLP-1 drugs significantly reduce CRP and TNF-alpha vs placebo and other diabetes drugs. Only 20-60% of CRP reduction is explained by weight loss. Complete
Altimmune's pemvidutide is a GLP-1/glucagon dual agonist designed specifically for MASH and obesity. Phase 2 data showed 10-15% weight loss and significant liver fat reduction at 4
Polycystic ovary syndrome affects 10% of women. GLP-1 drugs improve insulin resistance, reduce androgens, restore ovulation, and produce weight loss. Here's the evidence from clini
Survodutide Phase 2 NEJM data: 83% MASH improvement, 87% liver fat reduction, 64.5% fibrosis improvement. Glucagon mechanism explained. Phase 3 trials for obesity and liver disease
The FDA approved oral Wegovy in December 2025 based on OASIS 4 data: 16.6% weight loss at 64 weeks. Complete trial results, comparisons to injectable, and what it means for patient
Rapid weight loss reduces bone density, but major GLP-1 trials show no increase in fracture events. The SELECT trial, AAOS 2026 data, and what the evidence actually says about bone
CagriSema combines semaglutide with cagrilintide (amylin analog). REDEFINE 1: 22.7% weight loss at 68 weeks, 60% lost 20%+. NDA filed December 2025. Complete data breakdown.
The first direct comparison trial: tirzepatide lost 20.2% vs. semaglutide's 13.7% at 72 weeks. NEJM-published SURMOUNT-5 data, secondary endpoints, safety, and what the numbers act
Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data: 24.2% body weight loss at 48 weeks, 86% achieved normal liver fat. Here's every number from the
The FLOW trial is the first dedicated kidney outcomes trial for a GLP-1 drug. Semaglutide cut major kidney events by 24%, cardiovascular death by 29%, and was stopped early for eff
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Here's what the 41-page Federal Register notice actually says —
The Phase 3 ESSENCE trial showed semaglutide 2.4 mg resolved MASH in 62.9% of patients and improved liver fibrosis in 37%. Published in NEJM April 2025. FDA granted Priority Review
Complete GLP-1 pricing guide for 2026: Medicare Bridge at $50/mo, oral Wegovy at $149, compounded options, insurance, and manufacturer savings programs. Every price sourced.
GLP-1 weight loss plateaus are normal and documented in every major trial. Here's when they happen, why, and evidence-based strategies for breaking through stalls.
Systematic reviews confirm GLP-1 drugs increase testosterone in obese men by 1.39 ng/mL on average. How it works, fertility implications, and every major study explained.
222,942-patient study shows semaglutide users have 32% fewer tobacco-related medical encounters. Active trials, the dopamine mechanism, and what it means for smokers.
Complete GLP-1 eligibility guide: BMI requirements, qualifying conditions, Medicare coverage starting July 2026, insurance criteria, and who does not qualify. Every threshold expla
Does semaglutide help or worsen depression? A 100,000-person Swedish study, FDA safety reviews, and every major finding on GLP-1 medications and mental health — sourced and expla
No articles found matching your search.